

- A1
- (b) the complement of SEQ ID NO:214;
 - (c) sequences consisting of at least 20 contiguous residues of SEQ ID NO: 214;
 - (d) sequences that hybridize to SEQ ID NO: 214 under highly stringent conditions;
 - (e) sequences having at least 75% identity to SEQ ID NO: 214;
 - (f) sequences having at least 90% identity to SEQ ID NO: 214 and
 - (g) degenerate variants of SEQ ID NO: 214.

A2

11. (Amended) A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component selected from the group consisting of the polynucleotides of claim 1.

REMARKS

Applicants submit this response to the Office Action dated August 27, 2002. Claims 1, 3-4, 8, 11-in part, and 15 are currently under consideration in the present application. Following the above amendments, and as further discussed below in the context of the Examiner's rejections, claim 8 has been cancelled, and claims 1 and 11 have been amended. Applicants submit that each of these amendments is supported by the specification as filed and that no new matter has been added. For example, support for the above amendments can be found at page 11, lines 8 through 9, and page 27, lines 13 through 26. It is also noted that the above amendments are made without prejudice to prosecution of any or all subject matter removed and/or modified by this amendment in a related divisional, continuation and/or continuation-in-part. In addition, please find enclosed herewith a Supplemental Information Disclosure Statement.

Rejection Under 35 U.S.C. § 112 (enablement)

Claims 1, 3-4, 8, 11-in part, and 15 stand rejected under 35 U.S.C § 112, first paragraph, as allegedly containing subject matter that was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly